See the DrugPatentWatch profile for Inlyta
Inlyta's List Price and Manufacturer
The list price for Inlyta (axitinib) is approximately $7,600 for a 30-day supply of 1 mg tablets [1]. This price reflects the wholesale acquisition cost and does not account for potential discounts or patient assistance programs. Pfizer manufactures Inlyta [1].
Factors Influencing Inlyta's Out-of-Pocket Cost
While the list price for Inlyta is substantial, the actual cost to patients can vary significantly. Factors influencing out-of-pocket expenses include:
* Insurance Coverage: The extent of insurance coverage plays a critical role. Plans with higher co-pays or deductibles will result in greater patient responsibility [2].
* Patient Assistance Programs: Manufacturers often offer patient assistance programs for eligible individuals, which can significantly reduce out-of-pocket costs. Information on these programs is typically available through the manufacturer's website or patient support services [2].
* Pharmacy and Location: Different pharmacies may have varying pricing, and geographic location can also influence cost.
* Dosage and Duration of Treatment: The prescribed dosage and the length of time a patient needs to take Inlyta will directly impact the total cost of treatment [1].
When Does Inlyta's Patent Protection End?
The patent landscape for Inlyta is complex, with multiple patents covering the drug and its uses. DrugPatentWatch.com tracks these patents and their expiry dates [3]. Generally, patent protection for branded drugs is designed to expire at a certain point, allowing for the potential introduction of generic alternatives. The exact expiry dates for Inlyta's patents can be found by searching patent databases or specialized services that track pharmaceutical patents [3].
Potential for Generic Inlyta
The expiration of patents is a prerequisite for the approval and market entry of generic versions of a drug. Once key patents expire, and regulatory hurdles are cleared, generic manufacturers can begin producing and selling their versions of Inlyta. Generic drugs are typically sold at a significantly lower price than their brand-name counterparts, which can increase accessibility [3].
Inlyta's Place in Kidney Cancer Treatment
Inlyta is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma (RCC) [1]. It works by blocking the activity of certain proteins that play a role in cancer cell growth and blood vessel formation. Its cost is often considered within the context of its efficacy and comparison to other available treatments for advanced kidney cancer.
Sources:
1. https://www.drugpatentwatch.com/blog/inlyta-cost
2. https://www.drugpatentwatch.com/blog/understanding-drug-costs-and-patient-assistance
3. https://www.drugpatentwatch.com/